A rheumatologist at University of Washington initially resisted testing for TGF-beta-1 in a juvenile rheumatoid arthritis patient who was going blind; Shoemaker noted there are 75,000 published papers on TGF-beta-1, indicating the marker exists in peer-reviewed literature. After testing, TGF-beta-1 was found to be elevated and was causative; treatment normalized it and the patient regained vision.